Tag: Clarivate

new-clarivate-report-reveals-dynamic-global-trademark-landscape,-with-metaverse-and-nft-trends-increasingly-driving-trademark-filing-activity

New Clarivate Report Reveals Dynamic Global Trademark Landscape, With Metaverse and NFT Trends Increasingly Driving Trademark Filing Activity

May 4, 2022 Published by

 

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today a new report, Traversing the evolving trademark landscape: discover trends, challenges and opportunities through the lens of IP intelligence. According to the report, advances in the virtual world – the emergence of crypto-currency, the rise of the metaverse and surging popularity of non-fungible tokens (NFTs) – have helped propel Nice Class 9 (technology, computer hardware and software) filings from third place in 2011 to second by the end of 2021.

Since the first U.S. trademark application for NFTs was filed in August 2018, related trademark applications have soared over 9,000% and those for virtual goods or services increased 250% in 2021, according to Clarivate™ trademark research data. Brands from Louis Vuitton1 and Dolce and Gabbana, to Coca-Cola2 and even the Australian Open tennis event,3 are experimenting with NFTs.

The report also finds that despite continued socio-economic uncertainty, worldwide trademark filing activity increased globally for the 10th consecutive year. However, there was a notable exception to the overall rise in trademark filing activity in Class 10 (medical and diagnostic equipment), which fell 22% last year. This suggests that the flurry of commercial activity in response to the COVID-19 pandemic, particularly for masks or face coverings and other personal protective equipment, may have passed its peak.

Robert Reading, Head of Content Strategy, Clarivate said, “We live in a digital, hyper-connected and technologically advanced world where trends such as NFTs and the metaverse present both un-precedented opportunities and challenges to how intellectual property is created, managed and protected. Through the lens of trademark research intelligence, brands and organizations can better understand how to make confident business and brand decisions in a fast-evolving trademark landscape.”

Other key findings of the report include:

  • U.S. trademark applications for NFTs jumped almost seven-fold in the first two months of 2022.
  • Interest in the metaverse is driving a significant increase in applications using the term “Meta” and those for marks covering “virtual goods/services”.
  • Mainland China continues to power world trademark filing activity and made up almost 70% of global filing activity in 2021, followed by the United States (5%), India (3%), Brazil (3%) and South Korea (2%).
  • Mainland Chinese companies continue to dominate the list of top filers across multiple registers, accounting for five of the top ten filers – Xiaomi, Tencent, Alibaba, Huawei and Zhejiang Geely.
  • Nice Class 35 (retail, advertising, marketing and business services) dominated in Mainland China in 2021, similar to the worldwide trend. The alcoholic beverage sector in Mainland China experienced strong trademark filing growth, with Class 33 (alcoholic beverages excluding beer) seeing a 34% increase and Class 32 (beer and non-alcoholic beverages) up by 13% in 2021.
  • Despite a strong start and a record year for The United States Patent and Trademark Office (USPTO), filing volume steadily fell throughout 2021.
  • Mainland China was the source of 28% of all trademark applications filed at the USPTO in 2021, an increase of 4% from the previous year. Conversely, trademark applications from U.S. addresses fell by 3% in 2021.
  • The United Kingdom Intellectual Property Office (UKIPO) has been the fastest growing major trademark register in the world, growing 31% in 2020 and 38% in 2021.
  • South Korea ranks among the top five IP offices in the world, underlining its importance on the global IP stage. Trademark filing activity at the Korean Intellectual Property Office (KIPO) has been rising consistently and saw double digit year-on-year increases in filing volume between 2019 and 2021.

Reading concluded, “Organizations continue to face some of the most challenging business conditions today. Making informed brand decisions with certainty and speed to fuel progress and growth is getting harder. At Clarivate, we empower organizations with critical insights and IP management solutions that are designed to help them build and protect their most critical asset – their brand. In a world where organizations are operating in a borderless, highly competitive and increasingly online marketplace, curating and safeguarding unique and valuable brand identities will become ever more critical to business success.”

clarivate-demonstrates-2021-nobel-prediction-success-in-every-field-of-science-and-economics

Clarivate Demonstrates 2021 Nobel Prediction Success in Every Field of Science and Economics

October 14, 2021 Published by

 

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today celebrates the five new Nobel Laureates across the fields of science and economics who were accurately identified as potential Nobel Prize recipients. Each individual was awarded the designation of Citation Laureate™ as much as 12 years prior to being named by the Nobel Assembly. Clarivate is the only organization in the world to use quantitative data together with expert qualitative analysis to identify the pinnacle realm of scientific contributions recorded in the Web of Science.™ Using this approach, Clarivate identifies researchers ‘of Nobel class’ and forecasts those who could be awarded the Nobel Prize.

This year, Clarivate anticipated Nobel Laureates in each category of Physiology or Medicine, Physics, Chemistry and Economics, demonstrating the association between the citation record which reflects influence throughout a research community and peer judgement. This is the third time in 10 years that Citation Laureates named by Clarivate have been awarded a Nobel Prize in all four of these categories, following success in 2011 and 2013. Since 2002, there have been 64 Citation Laureates who have gone on to receive a Nobel Prize.

The five Citation Laureates named as Nobel Laureates in 2021 are:

  • The 2021 Nobel Prize for Physiology or Medicine, awarded to David Julius and Ardem Patapoutian, for their discoveries of receptors for temperature and touch.
    • David Julius was identified as a Citation Laureate seven years ago in 2014. At that stage, Julius’ top ten-cited papers in the Web of Science Core Collection had been cited 22,372 times, putting him in the very top tier of the citation elite. He is our 60th Nobel awardee and the 16th individual who has gone on to receive a Nobel in the field of Physiology or Medicine.
  • One half of the 2021 Nobel Prize for Physics was awarded to Giorgio Parisi, University of Sapienza, Rome, for ground-breaking contributions to our understanding of complex systems.
    • Giorgio Parisi was identified as a potential Nobel honoree by Clarivate just a few weeks ago, in September 2021. His appearance on the list caused great excitement in Italy. As a result, he was interviewed widely by media outlets prior to the Nobel announcement, as the Clarivate program is seen as an accurate weathervane for identifying researchers ‘of Nobel class’. This brings the tally for Physics to 17 people since 2002.
  • The 2021 Nobel Prize in Chemistry was awarded to Benjamin List and David McMillan for the development of asymmetric organocatalysis.
    • Citation analysts at Clarivate identified Benjamin List as a potential Nobel awardee in 2009 for his pioneering research in the development of asymmetric organocatalysis. This makes him our 62nd Citation Laureate who has gone on to receive the Nobel Prize, and the 9th in Chemistry.
  • The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, awarded jointly to David Card for his empirical contributions to labour economics and to Joshua Angrist and Guido Imbens for their methodological contributions to the analysis of casual relationships.
    • Both David Card and Joshua Angrist were welcomed into the Hall of Citation Laureates back in 2013, for their advancement of empirical microeconomics. Their award brings our tally of Citation Laureates to be recognized for Economics to 16. Our analysis at the time stated, “The range of topics that they have studied is remarkable: unemployment, wages, unions, immigration, education, health insurance, terrorism, income distribution, regulation, methods. Their common approach to answering fundamental questions about how markets work has plainly had a great impact—not only deep but broad as well.”

To explain the success of Clarivate in identifying future Nobel Laureates, David Pendlebury, Chief Citation Analyst at the Institute for Scientific Information at Clarivate said, “Accurately predicting who will be awarded a Nobel prize is a challenge, as there are so many worthy individuals to choose from. The Nobel committees consult with 3,000 experts and examine the work of 250-350 preliminary candidates in their qualitative analysis. Here at Clarivate, we start with the data – a quantitative analysis of papers with 2,000+ citations, and our team of experts then adds a layer of qualitative analysis.”

Joel Haspel, SVP Strategy, Science at Clarivate said: “Our analysts are particularly skilled at using citation data to identify researchers whose human ingenuity changes the world for the better. We can also identify potential Nobel awardees, often many years before they come to the attention of the Nobel committee. Parisi’s inclusion raised a particularly loud cheer from our worldwide colleagues – he has only been a Citation Laureate for a matter of weeks.”

Notes to editors:

Methodology:

Each year since 2002, analysts at the Institute for Scientific Information™ at Clarivate have drawn on Web of Science publication and citation data to identify influential researchers across the globe whose contributions to science have been extremely influential, even transformative in the research areas recognized by Nobel Prizes: Physiology or Medicine, Physics, Chemistry and Economics. The Web of Science is the world’s largest publisher-neutral citation index and research intelligence platform. It organizes the world’s research information to enable academia, corporations, publishers and governments to accelerate the pace of research. Out of some 52 million articles and proceedings indexed in the Web of Science since 1970, only 6,500 (or .01%) have been cited 2,000 or more times. It is from the authors of this group of papers that Citation Laureates are identified and selected – an approach unique to Clarivate in identifying researchers ‘of Nobel class’.

clarivate-to-acquire-proquest,-creating-a-leading-global-provider-of-mission-critical-information-and-data-driven-solutions-for-science-and-research

Clarivate to Acquire ProQuest, Creating a Leading Global Provider of Mission Critical Information and Data-Driven Solutions for Science and Research

May 17, 2021 Published by

 

Clarivate plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a definitive agreement to acquire ProQuest,  a leading global software, data and analytics provider to academic, research and national institutions, from Cambridge Information Group, a family-owned investment firm, and other partners including Atairos, for $5.3 billion, including refinancing of ProQuest debt. The consideration for the acquisition is approximately $4.0 billion in cash and $1.3 billion of equity. The transaction, which is subject to customary closing conditions, including regulatory approvals, is expected to close during the third quarter of 2021.

With a mission to accelerate and improve education, research and innovation, ProQuest delivers content and technology solutions to over 25,000 academic, corporate and research organizations in more than 150 countries. The acquisition will establish Clarivate as a premier provider of end-to-end research intelligence solutions and significantly expand its content and data offerings as the addition of ProQuest will materially complement the Clarivate Research Intelligence Cloud™.

By bringing together these two customer-focused businesses with a purpose to accelerate innovation at their core, we will create a world-leading software and information provider for research-focused organizations to fuel scientific discovery and innovation into the future.

Jerre Stead, Executive Chairman and CEO, Clarivate, said: “Clarivate and ProQuest are highly complementary businesses, each with a rich and storied heritage. We share the goal to accelerate innovation through research and knowledge sharing and together we will enable our customers to solve the world’s most complex challenges with content dating back centuries, and technologies that address the needs of 21st century customers.”

Andy Snyder, Chairman of ProQuest and CEO of Cambridge Information Group, said: “I have seen ProQuest evolve to meet our customers’ ever-changing needs over the last several decades and fully understand that the challenges and opportunities they face have never been greater. I am confident that the company will continue to have the resources required to maintain the impressive track record of innovation that our customers count on – to create a world leading organization in research and innovation.”

Upon completion of the transaction, two members of the ProQuest Board will join the Clarivate Board, including Andy Snyder, who will have the position of Vice Chairman of the Clarivate Board, and Michael Angelakis, Chairman and CEO of Atairos.

Compelling strategic benefits to drive future growth

  • Creates a world-leading software and content information provider for academia, governments, public libraries and corporations: Content aggregation, along with software solutions to connect and filter disparate information, is critical in today’s world of information overload. The combination of these two gold-standard organizations will provide a gateway to the world’s largest collection of interoperable, expertly curated content, including journal content, primary sources, dissertations, news, streaming video and more across multiple academic disciplines. Clarivate will continue to expand its market-leading software to enhance its discovery, sharing and management capabilities.
  • Opens new sales opportunities to drive growth in existing and complementary markets: Enterprise software is the fastest growing library market segment and has high customer loyalty due to workflows integrated in core library operations. This acquisition will provide Clarivate with access to complementary markets and varied users, including public libraries, research libraries, school districts and community colleges, with the opportunity to deliver new campus-wide platforms to provide a unified source of knowledge discovery.
  • Broadens our analytical offerings: The addition of ProQuest moves the academic analytical capabilities of Clarivate beyond its traditional realm of journal publication data and citations into a much wider range of information sources. There will be long-term predictive and prescriptive analytics opportunities from the enhanced combination of ProQuest’s data cloud with the billions of harmonized data points in the Clarivate Research Intelligence Cloud.

Financially compelling transaction

  • Accretive to Clarivate earnings per share: The transaction is expected to be double-digit accretive to Clarivate earnings in 2022 and mid-teens accretive in 2023.
  • Value-enhancing acquisition with significant opportunities to accelerate growth, create efficiencies and enhance margins: For 2020, ProQuest generated $876 million of revenue, 4% from organic growth, and $250 million of Adjusted EBITDA. The acquisition is expected to provide significant cost synergies, which, in addition to revenue synergies, is expected to drive both ProQuest and Clarivate Adjusted EBITDA growth and expand ProQuest’s Adjusted EBITDA margin.
  • Significant cost and tax savings opportunities: Clarivate expects to benefit from more than $100 million of cost synergies across the organization within the 15 – 18 months after the close of the transaction. Clarivate also expects to benefit from approximately $65 million in annual cash tax savings from the transaction structure.
  • Enhanced free cash flow generation: The acquisition is expected to generate strong cash flow that will enable Clarivate to reduce its debt, continue investing in product development and pursue additional business development opportunities.

Mukhtar Ahmed, President, Science at Clarivate, said: “Clarivate is building a globally connected and highly personalized experience for researchers, academic institutes and funders across the entire digital research value-chain, from ideation through to outcome. With this acquisition we will be able to further empower both present and future generations of academic and corporate researchers as they each pursue their journey of innovation.”

Matti Shem Tov, CEO, ProQuest, said: “Through this combination, ProQuest will be enabled to better serve the evolving needs of our customers by providing end-to-end solutions to our customers faster than we could on our own as well as expanding our global reach beyond our current capabilities. We look forward to a bright and exciting future for ProQuest and our customers.”

Financing

In connection with the transaction, Clarivate has secured a backstop consisting of a $4 billion fully committed bridge facility from Citi and Goldman Sachs & Co. LLC. Clarivate intends to obtain long-term financing from debt and equity markets before the closing of the transaction.

Advisors

Evercore is serving as lead financial advisor and Davis Polk & Wardwell LLP is serving as legal advisor to Clarivate.  Goldman Sachs & Co. LLC is serving as lead financial advisor to ProQuest with support from UBS Investment Bank and Morgan Stanley & Co. LLC. Fried, Frank, Harris, Shriver & Jacobson LLP is serving as legal advisor to ProQuest.

Clarivate reaffirming standalone 2021 outlook

For the year ending December 31, 2021, excluding the combination with ProQuest, Clarivate continues to expect:

  • Adjusted Revenues in a range of $1.79 billion to $1.84 billion1
  • Adjusted EBITDA in a range of $790 million to $825 million1
  • Adjusted EBITDA margins in a range of 44% to 45%1
  • Adjusted diluted EPS in a range of $0.74 to $0.791
  • Adjusted Free Cash Flow in a range of $450 million to $500 million1

Clarivate will provide an updated 2021 outlook to include the acquisition of ProQuest after closing of the transaction, which is expected to occur in the third quarter of 2021.

1See Reconciliation to Certain Non-GAAP measures” presented below for important disclosure and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this press release.

Conference call details

Clarivate will host a conference call and webcast to discuss the strategic and operating aspects of the ProQuest combination on Monday, May 17th at 8:00 a.m. Eastern Time. The conference call will be simultaneously webcast on the Investor Relations section of the company’s website.

Interested parties may access the live audio broadcast by dialing 1-888-317-6003 in the United States, 1-412-317-6061 for international, and 1-866-284-3684 in Canada. The conference ID number is 5893138. An audio replay will be available approximately two hours after the completion of the call at 1-877-344-7529 in the United States, 1-412-317-0088 for international, and 1-855-669-9658 in Canada. The Replay Conference ID number is 10156753. The recording will be available for replay through May 31, 2021.

clarivate-drugs-to-watch-report-highlights-four-likely-blockbusters-among-drugs-launching-in-2021

Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021

March 9, 2021 Published by

 

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of its annual “Drugs to Watch” list, identifying drugs entering the market or launching key indications in 2021 which are predicted to achieve blockbuster status by 2025.

Beyond the unprecedented achievements of the industry’s response to COVID-19, drug developers have advanced milestone treatments for conditions affecting millions of patients worldwide. This year’s Drugs to Watch list and corresponding analyses focus on treatments for chronic, progressive and often debilitating diseases and conditions, including Alzheimer’s, prostate cancer and congestive heart failure.

Despite a challenging year, biopharma companies managed to produce highly-effective vaccines and treatments aimed at preventing SARS-CoV-2. This year’s Drugs to Watch report also features a snapshot of the fast-emerging field of COVID-19 vaccines which analyzes vaccines that were granted emergency use authorizations/conditional approvals as of February 10, 2021. Learnings from some of the adjustments the industry made in response to the COVID-19 pandemic will likely shape biopharma R&D and commercialization well beyond the immediate crisis, including: faster clinical trials, a surge in investment, increased collaboration and more remote care and consultation.

Among new drugs and biologics that have either won approval or are on the cusp of doing so, Clarivate has identified four treatments that are likely to achieve blockbuster status, delivering annual sales of more than $1 billion, within five years. The 2021 Drugs to Watch include:

  • Aducanumab, developed by Biogen and Eisai – a potential game changer in the fight to build a pharmacopeia against Alzheimer’s disease, which affects an estimated 50 million patients worldwide. If approved, aducanumab would be the first disease-modifying therapy for Alzheimer’s disease and could unlock a monumental opportunity to radically change patient care and transform the market. In addition, demand for treatment could be enormous, potentially even decreasing willingness to forgo this treatment for an investigational drug in future clinical trials.
  • Bimekizumab, developed by UCB – offers significantly fewer side effects to patients with psoriasis, a condition affecting an estimated 2-3% of the global population, and a host of other autoimmune diseases. While bimekizumab is a late-class entrant providing incremental improvement over existing treatment options, it is expected to have best-in-class efficacy and fewer serious side effects.
  • Relugolix, developed by Takeda – one of the first of a new class of treatments, with an oral formulation to address prostate cancer, the second-most-common malignancy afflicting men, as well as endometriosis and uterine fibroids, painful conditions affecting millions of women. Its potential use for three indications increases its chances of success. The oral formulation provides advantages over the injectable GnRH agonist competitors, including convenience and better management of side effects.
  • Vericiguat, developed by Bayer and Merck – an innovative heart failure treatment and the first indicated specifically for high-risk, chronic heart failure with reduced ejection fraction (HFrEF), a particularly at-risk population. Vericiguat’s novel mechanism of action should result in its acceptance as an add-on therapy to existing treatments. It will likely find its niche among high-risk HFrEF patients, become a welcome addition to the treatment armamentarium and expand their treatment options.

Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare, Clarivate, said: “In the last five years we have seen an increase in approvals of innovative medicines at a rate more than double what it was a decade ago. A number of drivers have aligned to achieve this improvement, including greater insight into the biological roots of diseases, oncology research benefiting from the routine introduction of biomarkers to better target therapies, the emergence of gene and cell therapies and efforts by regulatory agencies to introduce processes to accelerate medicine assessment.”

Clarivate leverages proprietary data and insights from Cortellis Competitive Intelligence™, Disease Landscape & Forecast™, and Drug Timeline & Success Rates™ as well as 1000s of data points from within its wider intelligence cloud to produce the annual list of potential drugs for inclusion –from drugs that advanced to phase II trials or beyond in 2021. Each drug was researched and evaluated in its individual context by interrogating annual filings, drug pipelines, clinical trials, patents, chemistry, deals, regulatory status and more. Therapy area experts across a wide range of markets examined the various disease landscapes from all angles, reviewed the pricing strategies and explored the science underpinning the new medicines.

There is a high level of expectation of commercial success for each of the drugs featured in this year’s list, with some expected to tout improved safety vs. alternative therapies, while others will seek to highlight novel mechanisms of action. In addition to driving future innovation, these treatments have the potential to advance human health, redefine standards of care in their categories and save or improve patient lives.

Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. The new annual report further demonstrates how the combined expertise, data and technologies of Clarivate and Decision Resources Group (DRG), acquired by Clarivate in 2020, enable customers to make informed evidence-based decisions, boost clinical and commercial success, and bolster a robust, integrated platform of life science intelligence solutions from pre-clinical and clinical offerings.

The full Drugs to Watch report is freely available online here.

Join the conversation on Twitter: @clarivate #drugstowatch2021

The 2021 Clarivate Drugs to Watch List:

Methodology for the Clarivate Drugs to Watch 2021 Report
Data for this list were compiled from Cortellis Competitive Intelligence™, Disease Landscape & Forecast™, and Drug Timeline & Success Rates™. Cortellis Competitive Intelligence includes the broadest and deepest range of sources of intelligence across the R&D lifecycle, including annual filings, drug pipelines, clinical trials, patents, chemistry, deals, conferences and company announcements. Disease Landscape & Forecast provides comprehensive market intelligence and actionable insights across 180+ indications to help optimize long-term disease strategies. Drug Timeline & Success Rates is an analytic tool that applies statistical modeling and machine learning to reliably and accurately forecast drug development milestones, timelines and probability of success. Drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2021 were selected for analysis; drugs launched prior to 2021 were excluded. The dataset was then filtered for drugs that had total forecast sales of $1 billion or more in 2025. This filtering process produced a list of drugs which was then manually reviewed by our in-house experts and consultants to determine whether these products were likely to go to market in 2021, based on factors such as the company’s expected approval or launch dates. Following this manual review, four drugs to watch for 2021 were determined. Each drug was subsequently researched and evaluated in its individual context, including clinical trial results, regulatory status, the market for each drug (including analysis of competitor drugs) and regulatory designations (e.g., Orphan Drug, Priority Review). Data extraction – January 21, 2021. Our Drugs to Watch 2021 Report is based Clarivate’s current expectations based on existing data, but actual results derived from the drugs identified in the Report may differ significantly.

clarivate-announces-change-to-board-of-directors

Clarivate Announces Change to Board of Directors

January 19, 2021 Published by

Clarivate Plc (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Karen G. Mills, a member of the board of directors, has informed the Company of her decision to step down from the board to spend time on other endeavors. With Ms. Mills’ departure, the Clarivate Board will consist of 11 members.

Jerre Stead, Executive Chairman and CEO said: “On behalf of our colleagues, shareholders and the Board, I want to thank Karen for her significant contributions to Clarivate. Her vast experience and guidance since we went public in May 2019 has been extremely beneficial in helping us achieve tremendous growth.”

“As big data and artificial intelligence play a more important role in innovation, science and intellectual property, Clarivate has a bright future,” Ms. Mills said.

Latest Members

Recent AchievementsYou must be logged in to view earned achievements

What is a Wire Coin?

Find connections

Who is online

Latest Hashtags

#artificialintelligence #betting #blockchain #casino #esports #fintech #gaming #hiptherfestival #hipthers #igaming #slots #technology